References
- Pagnoux C, Guilpain P, Guillevin L. Churg–Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25–32
- Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, et al. Treatment of Churg–Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58: 586–594
- Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, et al. Churg–Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57: 686–693
- Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg–Strauss syndrome. Clin Exp Rheumatol 2003; 21: S69–S77
- Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, et al. ANCA and the Churg–Strauss syndrome. Ann Intern Med 2005; 143: 632–638
- Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, et al. The leucotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: A case-crossover study. Thorax 2008; 63: 677–682
- Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, et al. Prevalence and clinical significance of ANCA in Churg–Strauss syndrome. Arthritis Rheum 2005; 52: 2926–2935
- Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, et al. ANCA specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955–963
- Zwerina J, Axmann R, Manger B, Schett G. The emergence of antineutrophil cytoplasmic antibodies may precede clinical onset of Churg–Strauss syndrome. Arthritis Rheum 2009; 60(2)626–627
- Guilpain P, Auclair JF, Tamby MC, Servettaz A, Mahr A, et al. Serum eosinophil cationic protein: A marker of disease activity in Churg–Strauss syndrome. Ann NY Acad Sci 2007; 1107: 392–399
- Kiene M, Csernok E, Muller A, Metzler C, Trabandt A, et al. Elevated IL-4 and IL-13 production by TC lines from patients with Churg–Strauss syndrome. Arthritis Rheum 2001; 44: 469–473
- Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished TC IL-5 production. Rheumatology (Oxford) 2008; 47: 1104–1105
- Shiota Y, Matsumoto H, Kanehisa Y, Tanaka M, Kanazawa K, et al. Serum IL-5 levels in a case with allergic granulomatous angiitis. Intern Med 1997; 36: 709–711
- Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215–1228
- Pease JE. Asthma, allergy and chemokines. Curr Drug Targets 2006; 7: 3–12
- Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, et al. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006; 103: 16418–16423
- Rothenberg ME, Maclean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997; 185: 785–790
- Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001; 24: 682–687
- Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006; 116: 536–547
- Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, et al. Eotaxin-3 is involved in Churg–Strauss syndrome—A serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008; 47: 804–808